Last reviewed · How we verify
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects. Pharmacodynamic effects on biomarkers will also be assessed. This study will have two parts. In Part A, subjects will be randomized to active or placebo treatment in a 3:1 ratio and in Part B, to placebo or one of the six doses of active treatment in an equal ratio. A sufficient number of COPD subjects (male and female of non-child bearing potential) will be screened to ensure that approximately 30 subjects are enrolled and at least 20 evaluable subjects are obtained for Part A and approximately 35 subjects will be enrolled for Part B. In both the parts, subjects will receive study treatment once daily for 14 consecutive days. Placebo control will be included for a valid evaluation of adverse events attributable to treatment versus those independent of treatment.
Details
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 64 |
| Start date | Thu Jul 31 2014 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- GSK2269557 100 MCG
- GSK2269557 500 MCG
- PLACEBO
Countries
Germany